Original Article

Effects Of Coenzyme Q10 On Lipid Levels And Antioxidant Defenses In Rats With Fructose Induced Hyperlipidemia And Hyperinsulinaemia

K Modi, S Vishwakarma, R Goyal, P Bhatt

Keywords

antioxidant activity, coenzymeq10, fructose-induced hypertriglyceridemia, lipid levels

Citation

K Modi, S Vishwakarma, R Goyal, P Bhatt. Effects Of Coenzyme Q10 On Lipid Levels And Antioxidant Defenses In Rats With Fructose Induced Hyperlipidemia And Hyperinsulinaemia. The Internet Journal of Pharmacology. 2006 Volume 5 Number 1.

Abstract

Many clinical studies suggest that type-II diabetic patients are subjected to chronic oxidative stress. Using rats with fructose induced hyperglycemia, hyperinsulinaemia and hyperlipidemia, we investigated whether treatment with CoenzymeQ10, a component of mitochondrial oxidative phosphorylation improved carbohydrate and lipid abnormalities. Treatment with CoenzymeQ10 (10mg/kg, i.p., daily) for 3 weeks produced a significant decrease (P<0.05) in elevated levels of glucose, cholesterol, triglycerides, very low density lipoprotein, low density lipoprotein, atherogenic index and increased high density lipoprotein cholesterol levels and HDL-ratio without affecting serum insulin levels in fructose-fed rats. Furthermore, CoenzymeQ10 treatment also reduced lipid peroxidation and increased antioxidants such as superoxide dismutase, catalase and glutathione in the liver homogenates of the treated animals. In conclusion, CoenzymeQ10 treatment significantly improved abnormalities in carbohydrate and lipid metabolism of fructose fed rats, possibly by increasing the antioxidant defense mechanisms.

 

Introduction

Type-II Diabetes Mellitus is associated with abnormalities in carbohydrates and lipid metabolism that results in excessive production of reactive oxygen species [ROS] and oxidative stress1,2,3,4,5,6. Elevated glucose causes oxidative stress as a result of increased production of mitochondrial ROS formed through auto-oxidation, oxidative phosphorylation, glycosylation and glycosamine pathways7,8,9,10,11. Elevated free fatty acids can cause oxidative stress because of increased mitochondrial uncoupling of oxidative phosphorylation and β-oxidation leading to an increase in the production of ROS12. These molecules can function as signals to activate a number of cellular stress sensitive pathways like Advanced glycation end products (AGEs) and receptors for AGE (RAGE), Protein kinase C (PKC), Polyol pathways, Nuclear Factor κB (NFκB), NH2-terminal Jun kinases/Stress Activated Protein Kinases (JNK/ SAPK), p38 Mitogen Activated Protein (MAP) kinase and hexosamine pathways13,14,15,16,17,18. Activation of these pathways is not only linked to the development of late complications of diabetes13,19,20 but also to insulin resistance, β-cell and endothelial dysfunctions21,22,23.

If oxidative stress is the pathogenic mechanism leading from insulin resistance to overt diabetes, the ability of an agent to prevent or reverse oxidant stress can account for its clinical usefulness24,25. Conventional antioxidants scavenge ROS in a stoichiometric manner26. However, interrupting the overproduction of oxidants by the mitochondrial electron transport chain would normalize the pathways involved in the development of oxidative stress24. CoenzymeQ10 (CoQ10), also known as ubiquinone, is an endogenously synthesized antioxidant. It is a component of the oxidative phosphorylation in the mitochondria, which converts the energy in carbohydrates and fatty acids into ATP to drive cellular machinery 25. In diabetes, mitochondrial oxidative phosphorylation is significantly reduced; thus ATP production is reduced along with decreased level of CoQ1027. In addition to assisting electron transfer during oxidative phosphorylation, CoQ10 inhibits certain enzymes involved in the formation of free radicals and thus attenuates oxidative stress28.

Fructose feeding provides a model of hyperlipidemia, hyperglycemia and insulin resistance through the elevated synthesis of cholesterol, fatty acid and triglyceride in the liver29,30,31. The present study was conducted to observe whether CoQ10 improved carbohydrate and lipid abnormalities such as hyperglycemia, hyperlipidemia and hyperinsulinemia in fructose-fed rats.

Materials And Methods

Experimental animals

Male Sprague Dawley rats weighing 200-250 g, (Zydus Research Center, Ahmedabad, India) housed under well controlled conditions of temperature (22±2°C), humidity (55±5%) and 12/12-h light dark cycle were given access to food and water ad libitum. The protocol of the experiment was approved by the Institutional Animal Ethical Committee as per the guidance of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Social Justice and Empowerment, Government of India.

Treatment protocol

Animals were divided into 3 groups (n=6) and treated for three weeks: (1) Normal control (normal diet and water ad libitum and received vehicle solvent) (2) Fructose fed control (normal diet and 10 % fructose in drinking water and received vehicle solvent) (3) Fructose fed treated with Coenzyme Q10 (10 mg/kg i.p. daily).32 Changes in body weight, food and water intake were recorded. At the end of 3 weeks, blood samples were collected from the tail vein after 8 h fast and allowed to clot for 30 minutes at room temperature. Blood samples were centrifuged at 5000 rpm for 30 minutes. Serum was separated and stored at -20°C until biochemical estimations were carried out.

Biochemical analysis

The serum parameters were analyzed spectrophotometrically by using double beam UV-Visible spectrophotometer (Shimadzu UV- UV-Visible spectrophotometer, model 1601). Estimation of serum glucose (GOD-POD method), cholesterol (enzymatic method), triglyceride (enzymatic method) and HDL-cholesterol (phosphotungstate method) were carried out using respective diagnostic kits (Bayer Diagnostic Ltd. India). Serum insulin was estimated by a radioimmunoassay method from Bhabha Atomic Research Centre, Mumbai, India. VLDL-cholesterol and LDL-cholesterol were calculated as per Friedewald's equation33.

VLDL = Total serum triglycerides/5 LDL= Total serum Cholesterol - Total serum triglycerides/5-Total serum HDL-C HDL ratio = HDL–Cholesterol X 100 /Total serum Cholesterol - HDL-C Atherogenic Index34 = Total serum triglycerides/Total serum HDL-C

Estimation of antioxidants

After 3 weeks, animals were sacrificed, the liver was quickly removed and washed in ice-cold saline. One hundred milligrams of liver tissue was homogenized in ice-cold tri hydrochloride buffer (pH 7.2). The homogenate was centrifuged at 800 g for 10 min, followed by centrifugation of the supernatant at 12,000g for 15 min. The supernatant obtained was used for the estimation of reactive oxygen metabolites in terms of lipid peroxidation35, superoxide dismutase (SOD)36, catalase37, reduced glutathione (GSH)38, and total protein estimation39.

Statistical analysis

Results were analyzed statistically using one way analysis of variance- (ANOVA) followed Tukey's test. Data were considered statistically significant at p<0.05.

Results

Effects on body weight, glucose, insulin and lipid Profile

Fructose fed rats exhibited significant increase in body weight as compared to normal control rats (P<0.05). Treatment with CoQ10 in fructose fed rats reversed this increase in body weight (P<0.05). Fructose fed rats were hyperglycemic and hyperinsulinemic as compared to normal control animals (P<0.05). Treatment with Coenzyme Q10 in fructose fed rats reduced glucose level without affecting insulin levels (p<0.05). (Table 1). Fructose fed animals exhibited significantly higher serum cholesterol, triglyceride, VLDL-cholesterol and LDL-cholesterol levels whereas there was a decrease in HDL-cholesterol and HDL ratio as compared to normal control animals. CoQ10 treatment in fructose fed rats produced a significant decrease in serum cholesterol, triglycerides, VLDL-cholesterol, LDL-cholesterol levels, with an increase in HDL--cholesterol and HDL-ratio (Table 1). Furthermore, CoQ10 treatment to fructose fed rats exhibited significant improvement in atherogenic index (Table 1).

Figure 1
Table 1: Effects of Coenzyme Q10 Treatment on General Characteristics of the Experimental Animals Resembling Type II Diabetes.

Effects on antioxidant defenses

Fructose fed animals showed significant increase in lipid peroxidation in terms of amount of malondialdehyde and super oxide dismutase (SOD) in liver tissue homogenates when compared to normal control animals. Treatment with CoQ10 in fructose fed rats significantly decreased lipid peroxidation and increase SOD in liver tissue homogenates (P<0.05) (Table-2). Fructose fed rats showed significant decrease in catalase and glutathione levels in liver tissue homogenate as compared to normal control animals. Treatment with CoQ10 significantly increased catalase and glutathione levels in liver tissue homogenate (P< 0.05)(Table-2).

Figure 2
Table 2: Effects of Coenzyme Q10 Treatment on Antioxidant Parameters of the Experimental Animals Resembling Type II Diabetes.

Discussion

Evidence reviews that patients with type-II diabetes continually undergo oxidative stress, elevated glucose and free fatty acids increase levels of reactive oxidant species, islets have intrinsically low antioxidant enzyme defenses and antioxidant drugs and over expression of antioxidant enzyme rectify hyperglycemia and hyperlipidemia40. The present study was conducted to determine whether improving antioxidant enzyme defenses by treatment with Coenzyme Q10 (10mg/kg, i.p., daily, for 3 weeks) leads to an improvement in dyslipidemia and hyperglycemia in insulin resistant state. CoQ10 is responsible for assessing the electron transferring oxidative phosphorylation activity. It can also function beneficially by virtue of its free radical scavenging and inhibition of phospholipases activity28. Dyslipidemic patients with NIDDM exhibit hypertriglyceridemia and low levels of high density lipoprotein cholesterol41. Fructose feeding by the increased production of VLDL particles through the elevated synthesis of cholesterol, fatty acid and triglycerides in the liver42, causes insulin resistance accompanied by hyperlipidemia and hypertension43. Recently it was reported that continuation of fructose feeding caused down regulation of PPAR-α, which in turn leads to a reduction in triglycerides catabolism which is involved with LDL, Acyl Co-A oxidase and β-oxidation44. In accordance with these reports, in the present investigation we observed a state of hyperlipidemia, insulin resistance in fructose fed rats. Chronic CoQ10 treatment significantly decreased serum cholesterol and triglycerides levels in fructose fed animals, indicating improvement in lipid metabolism. Singh et al. reported the reduction in coronary artery plaque size, atherosclerotic index, cholesterol and triglyceride in Coenzyme Q10 treated transgenic diet fed animals45. The decrease in total cholesterol observed in the present investigation could be the result of increased HDL cholesterol or decreased VLDL cholesterol.

The triglyceride lowering effect of CoQ10 is likely to be the result of its LDL specific antioxidant activity as well as increased cellular antioxidant status45. Lipid peroxidation and covalent modification of apolipoprotein B oxidize LDL by lipid hydroperoxide breakdown46. Oxidized LDL is cytotoxic to vascular cells47,48, thus promoting release of lipids and lysosomal enzymes into the intimal extra cellular space and enhancing the progression of atherosclerotic lesions49, 50.

FFA and glucose overload increases the generation of acetyl CoA which in turn increases the production of electron donors from the tricarboxylic acid cycle. This increases the membrane potential, because protons are pumped across the mitochondrial inner membrane in proportion to electron flux through the electron transport chain. Inhibition of electron transport at complex III by increased membrane potential increases the half-life of free radical intermediates of CoQ10 which reduces O2 to superoxide51. According to an intra peritoneal glucose tolerance test, treatment with antioxidants retained glucose stimulated insulin secretion and moderately decreased the blood glucose levels52. In the present study, CoQ10 treatment reduced the blood glucose levels in fructose fed animals without affecting hyperinsulinemia. Under diabetic condition, JNK is activated by oxidative stress and involved in the suppression of insulin gene expression52. The effect on hyperinsulinemia in the present study could have been better justified had the treatment been for a longer duration. The beneficial effects of antioxidant gene overexpression in protecting β-cell function in a ribose related model of type II diabetes was recently reported53.

Pro-oxidants and markers for oxidative tissue damage, such as 8-hydroxy-deoxy guanine, 4-hydroxy-2-nonenal (HNE) proteins, 8-epi-prostaglandinF2α, hydroperoxides and oxidation of DNA bases, have been reported to be elevated in serum, plasma, white blood cells and pancreas biopsies of patients with type-II diabetes2,46,51. Paolisso et al. reported that intravenous infusion of glutathione in type-II diabetic patients improved insulin secretion and glucose tolerance during oral glucose tolerance tests54. In the present study, CoQ10 treatment significantly decreased lipid peroxidation and increased SOD, catalase and reduced glutathione levels in the liver tissue homogenate, which might be the result of a decrease in oxidative stress. In coronary artery disease patients, CoQ10 supplements was also associated with a significant reduction in thiobarbituric acid reactive substances, malondialdehyde and diene conjugates55

In conclusion, CoQ10 a provitamin and a mitochondrial free radical scavenger was found to significantly improve deranged carbohydrate and lipid metabolism of experimental fructose diet induced insulin resistant state in rats. The mechanism of its in-vivo antihyperlipidemic and antidiabetic action appears to be its mitochondrial antioxidant activity. This study emphasis the therapeutic potential of CoQ10 along with antidiabetics in the treatment of type II diabetes.

Acknowledgement

We thank Troikaa Pharmaceuticals Ltd., Zydus Research Center, Ahmedabad, India, for gifting sample of Coenzyme Q10 and animals for this research work.

Correspondence to

Ramesh K. Goyal Department of Pharmacology, L. M. College of Pharmacy, Ahmedabad, India. E-mail: ketan_modi11@rediffmail.com

References

1. Ghiselli, A., Laurenti, O., De Mattia, G., Maiani, G., and Ferro-Luzzi, A. 1992. Salicylate hydroxylation as an early marker of in vivo oxidative stress in diabetic patients. Free Radical Biology and Medicine 13, 621-26.
2. Gopaul, N.K., Anggard, E.E., Mallet, A.I., Betteridge, D.J., Wolff S.P., and Nourooz-Zadeh, J. 1995. Plasma 8 epi- PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Letter 368, 225-29.
3. Nourooz-Zadeh, J., Tajaddini-Sarmadi, J., McCarthy, S., Beteridge, D.J., and Wolff, S.P. 1995. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 44, 1054-58.
4. Rehman, A., Nourooz-Zadeh, J., Moller, W., Tritschler, H., Pereira, P., and Halliwell, B. 1999. Increased oxidative damage to all DNA bases in patients with type-II diabetes mellitus. FEBS Letter 448, 120-22.
5. Shih, P.T., Elices, M.J., Fang, Z.T., Ugarova, T.P., Strahl, D., Territo, M.C., Frank, J.S., Kovach, N.L., Cabans, C., Berliner, J.A., and Vora, D.K. 1999. Minimally modified low density lipoprotein induces monocyteadhesion to endothelial connecting segment I by activating B1- integrin. Journal of Clinical Investigation. 103, 613-25.
6. Sakuaba, H., Mizukani, H., Yagihashi, N., Wada, R., Hanyu, C., and Yagihashi, S. 2002. Reduced cell mass and expression of oxidative stress related DNA damage in the islet of japanese type-II diabetic patients. Diabetologia 45, 85-96.
7. Wolff, S.P., and Dean, R.T. 1987. Glucose autooxidation and protein modification: the potential role of autoxidative glycosylation in diabetes. Biochemical Journal 245, 243-50.
8. Hunt, J.V., Dean, R.T., and Wolff, S.P. 1988. Hydroxyl radical production and autooxidative glycosylation: glucose auto oxidation as the cause of protein damage in experimental glycation model of diabetes mellitus and ageing. Biochemical Journal 256, 205-12.
9. Kaneto, H., Xu, G., Fuji, N., Kim, S., Bonner, W.S., and Weir, G.C. 2002. Involvement of C-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. Journal of Biological Chemistry 277, 30010-18.
10. Nishikawa, T., Edelstein, D., Du, X.L., Yamagishi, S., Matsumara, T., Kaneda, Y., Yorek, M.A., Beebe, D., Oates, P.J., Hammes, H.P., Giardino, I., and Brownlee, N. 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 404, 787-90.
11. Bayes, JW. 1991. Role of oxidative stress in development of complications in diabetes. Diabetes 40, 405-12.
12. Hayden, M.R., Tyagi, S.C., and Kerklo, M.M. 2005. Type-II diabetes mellitus as a conformation disease. Journal of Pancrease 6, 287-302.
13. Rosen, P., Nawroth, P.P., and King, G. 2001. The role of oxidative stress in the onset and progression of diabetes and its complication: a summary of a congress series sponsered by UNESCO-MCBN, the American Diabetes Association and the German Diabetes society. Diabetes 17, 189-212.
14. West, I.C. 2002. Radicals and Oxidative stress in diabetes. Diabetes Medicine 17, 171-80.
15. Giugiano, D., Ceriello, A., and Paolisso, G. 1995. Diabetes mellitus, Hypertension and cardiovascular disease: which role for oxidative stress? Metabolism 44, 363-68.
16. Mohamed, A.K., Bierhaus, A., and Schiekofer, S. 1999. The role of oxidative stress and NF B activation in late diabetic complications. Biofactors 10, 157-67.
17. Stehouwer, C.D., and Schaper, N.C. 1996. The pathogenesis of vascular complication of diabetes mellitus. One voice or many? European Journal of Clinical Investigation 26, 533-43.
18. Yaqoob, M., Patrick, A.W., and McClelland, P. 1993. Relationship between markers of endothelial dysfunction, oxidant injury and tubular damage in patients with insulin dependent diabetes mellitus. Clinical Science 85, 557-62.
19. Brownlee, M. 2000. Negative consequences of glycation. Metabolism 49, 9-13.
20. Brownlee, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-20.
21. El Assad, W., Buteau, J., Peyot, M.L., Nolam, C., Roduit, R., and Hardy, S. 2003. Saturated fatty acids synergies with elevated glucose to cause pancreatic beta cell death. Endocrinology 144, 4154-63.
22. Piro, S., Anello, M., Di Pietro, C., Lizzio, M.N., ,Patane, G., Rabuazzo, A.M., Vigneri, R., and Purello, M. 2002. Chronic expression to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress. Metabolism 51, 1340-47.
23. Cerinello, A., and Motz, E. 2004. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes and cardiovascular disease? The common soil hypothesis revisited. Arteriosclerosis, Thrombosis, and Vascular Biology 24, 816-31.
24. Ceriello, A. 2003. New insights on oxidative stress and diabetic complications may lead to a "Casual"antioxidant therapy. Diabetes Care 26, 1589-96.
25. Ernsteer, L., and Dallner, G. 1995. Biochemical, physiological and medical aspects of ubiquinone function. Biochemica et Biophysica Acta 1271, 195-204.
26. Stahl, W., and Sies, H. 1997. Antioxidant defense: vitamins E and C and carotenoids. Diabetes 46, S14-18.
27. Kucharska, J., Braunova, Z., and O Uliena, I. 2000. Deficit of coenzyme Q10 in heart and liver mitochondria of rats with streptozotocin-induced diabetes. Physiological Research 49, 411-18.
28. Stocker, R., and Frei, B. 199. Endogenous antioxidant defenses in human blood plasma, in Oxidative Stress: Oxidants and Antioxidants. (H Sies ed., Academic, London), 213-43.
29. Zavaroni, I., Chem, Y.D.L., and Reaven, G.M. 1982. Studies of the mechanism of fructose-induced hypertriglyceridemia in the rat. Metabolism, 31, 1077-83.
30. Thorburn, A.W., Storlien, LH., Jenkins, A.B., Khouri, S., and Kraegen, E.W. 1989. Fructose induced in vivo insulin resistance and elevated plasma triglyceride levels in rats. American Journal of Clinical Nutrition 49, 1155-63.
31. Hwang, I.S., Ho, H., Hoffman, B.B., and Reaven, G.M. 1987. Fructose induced insulin resistance and hypertension in rats. Hypertension 10, 512-51.
32. Rauscher, F.M., Sanders, R.A., and Watkins, J.B. 3rd. 2001. Effects of coenzyme Q10 treatment on antioxidant pathways in normal and streptozotocin-induced diabetic rats. Journal of Biochemical and Molecular Toxicology 15, 41-45.
33. Friedewald, W.T., Lewy, R.I., and Fredrickson, D.S. 1972. Estimation of low-density lipoprotein cholesterol in plasma, without use of the preparative centrifuge. Clinical Chemistry 18, 499-504.
34. Pandya, N., Santani, D., and Jain, S. 2006. Antioxidant activity of ezetimibe in hypercholesterolemic rats. Indian Journal of Pharmacology 38, 205.
35. Ohkawa, H., Ohis, N., and Yagi, K. 1979. Assay of lipid peroxides in animal tissue by thiobarbituric reaction. Analytical Biochemistry 95, 351-59.
36. Mishra, H., and Frodvich, I. 1972. The role of superoxide anion in the auto-oxidation of epinephrine and a simple assay for superoxide dismutase. Journal of Biological Chemistry 247, 3170-77.
37. Aebi, H. 1974. Assay of catalase In Methods in enzymology ed. by L. Packer, (Academic Press, New York) 105, 121-27.
38. Beutler, E., and Kelly, B. 1963. The effect of sodium on RBC glutathione. Journal of Experimentia 19, 96-103.
39. Lowry, O., Rosenbrough, N., and Farr, A. 1951. Protein measurement with the Fiolin-Phenol reagent. Journal of Biological Chemistry 193, 265-75.
40. Robertson, R.P., Harmon, J., Oanh, P., Tran, T., and Poitout, V. 2004. cell glucose toxicity, lipotoxicity and chronic oxidative stress in type II diabetes. Diabetes 53, S119-24.
41. Durrington, P.N. 1999. Diabetic dyslipidemia Bailersm. Clinical Endocrinology and Metabolism, 13, 265-78.
42. Taghibiglov, C., Carpentier, A., and Van Iderstine, S.C. 2000. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Journal of Biological Chemistry 275, 8416-25.
43. Vasdev, S., Longerich, L., and Gill, V. 2004. Prevention of fructose induced hypertension by diet vitamin. Clinical Biochemistry 37, 1-9.
44. Roglans, N., Sanguino, E., Peris, C., Alegret, M., Nazquez, M., Adzet, T., Diaz, C., Hernandez, G., Laguna, J.C., and Sanchez, R.M. 2002. Atorvastatin treatment induced peroxisome proliferator activated receptor alpha expression and decreased plasma non esterified fatty acids and liver triglyceride in fructose fed rats. Journal of Pharmacology and Experimental Therapeutics 302, 232-39.
45. Singh, R.B., Shinde, S.N., and Chopra, R.K. 2000. Effect of CoQ10 on experimental atherosclerosis and chemical composition & quality of atheroma in rabbits. Atherosclerosis 148, 275-82.
46. Lynch, S.M., Morrow, J.D., Robert, L.J., and Frei, B. 1994. Formation of non-cyclo oxygenase derived prostanoids, (F2-isoprostares) in plasma and low-density lipoprotein exposed to oxidative stress in vivo. Journal of Clinical Investigation 93, 998-1004.
47. Rabinovitch, A., Suarez-Pinzon, W.J., Strynadka, K., Lakey, J.R., and Rajotte, R. V. 1996. Human pancreatic islet -cell destruction by cytokines involves oxygen free radicals and aldehyde production. Journal of Clinical Endocrinology and Metabolism 81, 3197-3202.
48. Ludvigsson, J. 1993. Intervention at diagnosis of type-I diabetes using antioxidants of photopheresis. Diabetes Metabolism and Review 9, 329-36.
49. Suzuki, S., Hinkio, Y., and Komatu, K. 1999. Oxidative damage to mitochondrial DNA and its relationship to diabetes complications. Diabetes Research and Clinical Practice, 45, 161-68.
50. Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C., and Witztum, J.L. 1989. Beyond cholesterol: Modification of low-density lipoprotein that increase to atherogenicity. New England Journal of Medicine 320, 915-24.
51. Shin, C.S., Moon, B.S., Park, K.S., Chung, M.H., and Lee, H.K. 2001. Serum 8-hydroxy guanine levels are increased in diabetic patients. Diabetes Care 24, 733-37.
52. Yoshitaka, K., and Hideaki, K. 2004. Role of oxidative stress in pancreatic beta cell dysfunction. Annals of the New York Academy of Sciences 1011, 168-76.
53. Tanaka, Y., Tran, P.O., Harmon, J., and Robertson, R.P. 2002. A role for glutathione peroxidase in protecting pancreatic beta cells against oxidative stress in a model of glucose toxicity. Proceedings of the National Academic Sciences, 99, 12363-68.
54. Paolisso, G., Giugliano, D., Pizza, G., Gambardella, A., Tesaauro, P., Varricchio, M., and D'Onofrio, F. 1992. Glutathione infusion potentiates glucose-induced insulin secretion in aged patients with impaired glucose tolerance. Diabetes Care 15, 1-7.
55. Singh, R.B., Niaz, M.A., Rastogi, S.S., Shulka, P.K., and Thakur, A.S. 1999. Effect of hydrosoluble CoQ10 on blood pressure and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 13, 203-08.

Author Information

Ketan P. Modi, M. Pharm
Department of Pharmacology, Shri B. M. Shah College of Pharmaceutical Education & Research

Santosh L. Vishwakarma, Ph.D.
Department of Pharmacology, L. M. College of Pharmacy

Ramesh K. Goyal, Ph.D.
Department of Pharmacology, L. M. College of Pharmacy

Parloop A. Bhatt, Ph.D.
Department of Pharmacology, L. M. College of Pharmacy

Your free access to ISPUB is funded by the following advertisements:

Advertisement